About Arzeda
Arzeda is a company based in Seattle (United States) founded in 2008 by Eric Althoff, David Baker, Daniela Grabs-Rothlisberger, and Alexandre Zanghellini. Arzeda has raised $94.96 million across 21 funding rounds from investors including W. L. Gore & Associates, United States Department of Agriculture and Bunge. The company has 66 employees as of December 31, 2024. Arzeda offers products and services including Intelligent Protein Design Technology and Reb M. Arzeda operates in a competitive market with competitors including Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
- Headquarter Seattle, United States
- Employees 66 as on 31 Dec, 2024
- Founders Eric Althoff, David Baker, Daniela Grabs-Rothlisberger, Alexandre Zanghellini
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Arzeda Corp
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$94.96 M (USD)
in 21 rounds
-
Latest Funding Round
$4.51 M (USD), Series B
Aug 28, 2025
-
Investors
W. L. Gore & Associates
& 19 more
-
Employee Count
66
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Arzeda
Arzeda offers a comprehensive portfolio of products and services, including Intelligent Protein Design Technology and Reb M.
AI tool for creating new proteins and enzymes for sustainability
Cost-effective stevia alternative for better taste in food industry
People of Arzeda
Unlock access to complete
Funding Insights of Arzeda
Arzeda has successfully raised a total of $94.96M across 21 strategic funding rounds. The most recent funding activity was a Series B round of $4.51 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Arzeda
Arzeda has secured backing from 20 investors, including venture fund and institutional investors. Prominent investors backing the company include W. L. Gore & Associates, United States Department of Agriculture and Bunge.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Locked | Locked | Locked | |
|
VC firm that does early stage investments in the US
|
Locked | Locked | Locked | |
|
Venture capital investments are directed toward agriculture and food sectors.
|
Locked | Locked | Locked |
Investor details for Arzeda
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Arzeda
Investment portfolio details for Arzeda
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Arzeda
Detailed financials for Arzeda
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Arzeda Comparisons
Peer comparison for Arzeda
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Arzeda
Arzeda operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein-based assays are developed for life science research.
|
|
| Locked | Locked | Locked |
A proteomics platform is developed for analyzing the human proteome.
|
|
| Locked | Locked | Locked |
Peptide-based therapeutics are developed for cancers and immune disorders.
|
|
| Locked | Locked | Locked |
Proteomics services are delivered via discovery and targeted platforms.
|
|
| Locked | Locked | Locked |
Digital platform transforming the delivery of biologic medicines
|
|
| Locked | Locked | Locked |
Provider tools to help researchers with protein analysis
|
Detailed competitors of Arzeda
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Arzeda
Complete news archive for Arzeda
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arzeda
Arzeda was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Arzeda is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Alexandre Zanghellini is the current CEO of Arzeda. They have also founded this company.
Arzeda is a funded company, having raised a total of $94.96M across 21 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Arzeda is 66.
Arzeda was founded in 2008 in Seattle, United States, within the biotechnology sector. Computational enzyme design and protein optimization are integrated with metabolic bioengineering to produce novel synthetic enzymes. Designer cell factories are engineered for large-scale chemical manufacturing. Operations focus on bridging gaps in enzyme functionality through targeted innovations, supporting industrial processes in sustainable production.
Arzeda's top competitors include Somalogic, Nautilus Biotechnology and Elektrofi.
Arzeda offers Intelligent Protein Design Technology and Reb M.
Arzeda has 20 investors. Key investors include W. L. Gore & Associates, United States Department of Agriculture, Bunge, Sofinnova Partners, and Fall Line Capital.